Table 5. . Sensitivity analyses results.
| Item | CladT cost | DMF cost | CladT QALY | DMF QALY | Difference in costs | Difference in QALY | Cost per QALY gained/Cost–effectiveness probability |
|---|---|---|---|---|---|---|---|
| Base case | 199,884€ | 274,625€ | 6.6577 | 6.4657 | -74,741€ | 0.1920 | CladT is dominant: 94.1%† |
| Time horizon | |||||||
| 20 years (10 years more) | 355,683€ | 513,685€ | 11.3694 | 10.8033 | -158,002€ | 0.5661 | CladT is dominant: 96.6%† |
| 40 years (30 years more) | 555,819€ | 826,795€ | 16.9660 | 15.6734 | -270,976€ | 1.2926 | CladT is dominant: 96.6%† |
| Treatment continuation after initial treatment | |||||||
| Less than 20% of the base case cost | 193,169€ | 265,653€ | 6.5382 | 6.3585 | -72,484€ | 0.1797 | CladT is dominant: 95.5%† |
| Reduction in purchasing cost of CladT and DMF (20%) | 184,671€ | 249,421€ | 6.8211 | 6.6131 | -64,750€ | 0.2080 | CladT is dominant: 95.3%† |
| Societal perspective (including labor costs) | 306,700€ | 388,337€ | 6.1883 | 6.0484 | -81,637€ | 0.1399 | CladT is dominant: 94.1%† |
| 20% discount on the price of CladT and 50% on the price of DMF | 192,545€ | 237,479€ | 6.6727 | 6.4772 | -44,934€ | 0.1955 | CladT is dominant: 95.3%† |
†
CladT treatment is dominant: it is more effective with lower costs, for a willingness to pay of 25,000 € per QALY gained.
CladT: Cladribine tablet; DMF: Dimethyl fumarate; QALY: Quality-adjusted life year.